

1 **Title**

2 **Determinants of HIV-1 late presentation in a cohort of Portuguese HIV-1 patients**

3 **Authors**

4 Ana Cláudia Miranda*¹, Mafalda Miranda*², Marta Pingarilho², Victor Pimentel², João Torres¹,
5 Susana Peres¹, Teresa Baptista Alberto¹, Perpetua Gomes^{3,4}, Ana Abecasis², Kamal Mansinho¹

6 **Affiliations**

7 1- Serviço de Doenças Infecciosas, Centro Hospitalar de Lisboa Ocidental, Hospital de Egas
8 Moniz, Lisboa, Portugal

9 2- Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina
10 Tropical/Universidade Nova de Lisboa (IHMT/UNL), Lisboa, Portugal

11 3- Laboratório de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisboa, Portugal

12 4- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de Ciências
13 da Saúde Egas Moniz, Caparica, Portugal

14 *These authors contributed equally for this work

15

16 **Abstract**

17 **Background:** Undiagnosed HIV-1 patients still account for 25% of worldwide HIV patients.

18 Studying late presenters for HIV care may help to identify characteristics of such patients.

19 **Objective:** The present study aims to identify factors associated with late presentation (LP) and
20 late presentation with advanced disease (LPAD) based on a population of patients followed in
21 a Portuguese hospital between 1984 and 2017.

22 **Methods:** Sociodemographic and clinical data from infected patients with HIV-1 aged 18 years
23 and older, followed in Egas Moniz Hospital, in Portugal were collected.

24 **Results:** Of the 907 patients included in this study, 68.7% were males and the median age was
25 37 years (IQR 30-47). 459 patients (50.6%) were LP and, of these, 284 patients (61.9%) were
26 LPAD. The LP population mostly originated from Portugal and Sub-Saharan Africa (64.4% and
27 28.8%; $p=0.004$) and the HIV exposure category mainly heterosexuals and MSM (57.0% and
28 24.9%; $p<0.001$). The stage of disease and viral load at diagnosis were significantly associated
29 with both LP and LPAD ($p<0.001$). Factors associated with LP in the logistic regression included
30 age at diagnosis lower than 30y (aOR 0.34; 0.17-0.68; $p=0.002$) and origin from Sub-Saharan
31 Africa (aOR 2.24; 1.44-3.50; $p<0.001$).

32 **Conclusion:** Late presentation is a major obstacle to halt the HIV epidemic. In this population,
33 the majority of newly diagnosed HIV-infected individuals were late presenters. Our results
34 characterize vulnerable populations that should be frequently tested for HIV.

35 **Keywords:** HIV-1 infection, Late presentation, Late presentation with advanced disease

36

37 Introduction

38 Human Immunodeficiency Virus (HIV) continues to be one of the main public health issues. In
39 2018 there was 1.7 million people newly infected worldwide and 973 new cases were reported
40 in Portugal [1, 2]. Early diagnosis is vital to achieve the objectives proposed by the WHO: the
41 95-95-95 target to end the pandemic by 2030: diagnosing 95% of people living with HIV, 95%
42 of diagnosed on treatment, and 95% of people on treatment viral suppressed [3]. However,
43 people living with HIV who do not know their status, account for 25% of the total infected
44 people worldwide (9.4 million people) [4]. In the European Union it is estimated that Late
45 Presenters (LP) represent around 49-54% of cases and Late Presenters with Advanced Disease
46 (LPAD) are around 33-42% of HIV cases [5]. According to the last Portuguese report, in 2018,
47 LP cases accounted for 55.8% and LPAD cases accounted for 34.3% of HIV infection [2].
48 Importantly, the proportion of LP cases among newly diagnosed is increasing, indicating that
49 we are leaving some older cases of undiagnosed patients behind.

50 According to the European Late Presenter Consensus working group, Late presenters (LP) were
51 defined as presenting a TCD4⁺ count lower than 350 cells/mm³ or an AIDS defining event,
52 regardless of TCD4⁺ cell count [6]. A subgroup of late presenters, called late presenters with
53 advanced disease (LPAD) are characterized by presenting a TCD4⁺ count lower than 200
54 cells/mm³ or an AIDS-defining event, regardless of TCD4⁺ cell count. This latest subgroup
55 particularly is at greater risk of severe disease and death [7,8]. The current guidelines for LP
56 and LPAD patients, suggest that they are unable to fully benefit from antiretroviral therapy
57 (ART), leading to poorer outcomes in treatment. This late entry to care can not only have an
58 impact in individual's morbidity and mortality, but also can increase the risk of onward
59 transmission due to unawareness of their HIV status, with an impact on the control of the
60 pandemic [9–11].

61 The present study has the objective of identifying determinants of late presentation (LP) and
62 late presentation with advanced disease (LPAD). To do this, we analyzed a population of
63 patients followed up in a Portuguese hospital, diagnosed between 1984 and 2017.

64 **Methods**

65 **Study Group**

66 Clinical and socio-demographic information from 907 HIV-1 infected patients was collected
67 during routine clinical care of patients followed in Hospital Egas Moniz, which is part of Centro
68 Hospitalar de Lisboa Ocidental (CHLO), Lisbon, Portugal, between 1984 and 2017. Patients
69 were aged 18 years and over.

70 **Statistical analysis**

71 Descriptive analysis was conducted. The proportion and median (interquartile range, IQR) of
72 LP, NLP and LP-AD was calculated for every categorical and continuous variable, respectively.
73 Our interest variables were compared with the categorical variables with Chi-square test, and
74 continuous variables with t-test for independent samples.

75 To study the association between our dependent variable and the independent variables,
76 logistic regression models were calculated. We first presented the logistic regression with the
77 unadjusted odds ratios (uOR) and confidence intervals at 95% (95%CI), variables with a p-value
78 <0.05 were considered to enter the model. We calculated the logistic regression model with
79 the stepwise mode, which lead to the construction of the final model. The final model for LP vs
80 NLP was adjusted for gender, this variable was forced into the model regardless of its
81 significance and the reference class were women, and the final model for LP vs LP-AD was
82 adjusted for gender and age at diagnosis. Results were considered statistically significant when
83 $p<0.05$. The odds ratio and 95% confidence intervals were calculated for the variables of the
84 final model. Data was analyzed using SPSS for Windows (Version 23.0).

85 **Ethics**

86 The protocol was in accordance with the declaration of Helsinki and approved by the Ethical
87 Committee of Centro Hospitalar de Lisboa Ocidental (108/CES-2014). This database contains
88 anonymized patients' information, including demographic and clinical data from patients
89 followed in Hospital Egas Moniz between 1984-2017.

90 **Results**

91 Among 907 HIV-1 infected patients included in the analysis the median age was 37 (IQR: 30.0-
92 47.0) years and 68.7% were males (Table 1). 459 patients (50.6%) were LP and, of these, 284
93 patients (61.9%) were LPAD. Heterosexuals and Portuguese originated patients presented a
94 higher proportion in this study population, 52.3% and 67.7% respectively. CD4 count at
95 diagnosis and viral load at diagnosis (\log_{10}) presented a median of 342 cells/mm³ (IQR 155-554)
96 and 4.8 copies/mL (IQR 4.2-5.4), respectively. Patients at stage A of HIV infection accounted
97 for 66.8% of the population of patients, when compared to stages B and C.

98 Characteristics of patients stratified according to time of presentation are presented in Table
99 1. In this sample, males accounted for the bigger proportion of LP (69.7%); 71.1% of those
100 being LPAD. No statistical differences according to gender were found for LP and LPAD
101 populations. The median age for LP was 39.5 (IQR 32-50; $p < 0.001$) and the age group between
102 31-55yo ($p < 0.001$) represented 64.2% of LP, significantly higher when compared with the
103 other age groups (≤ 30 and ≥ 56 ; $p < 0.001$). The median age for LPAD, 41 (IQR 32.25-51;
104 $p = 0.049$), was higher than LP. The median CD4 count for LP was 158 cell/mm³ (IQR 59-250) and
105 for LPAD was 83.5 cells/mm³ (IQR 33-144). LP population was mainly from Portugal and Sub-
106 Saharan Africa (64.4% vs 28.8%) and the HIV exposure category were mainly heterosexuals and
107 MSM (57.0% vs 24.9%). In the univariate analysis, both region of origin and HIV exposure
108 category were associated with LP ($p < 0.001$), but not associated with LPAD. Clinical
109 characteristics, as stage of disease and viral load at diagnosis were associated with both LP and

110 LPAD ($p<0.001$), for LP stage A had the higher proportion 48.6%, but for LPAD the stage C had
111 higher percentage, 46.4%.

112 In the unadjusted model (Table 2), for LP vs non-LP, no significant differences were found
113 between gender. In the HIV exposure category, significant differences were found for MSM
114 compared with heterosexuals, with a higher proportion of heterosexuals among LP.
115 Furthermore, significantly more immigrants from Sub-Saharan Africa were LP when compared
116 to native Portuguese. In LP vs LPAD unadjusted model significant differences were found in
117 stage of infection, youngest age group compared to the older one (LPAD are older) and viral
118 loads higher than 5.1 compared to viral loads lower than 4.0, as consistent with evolution of
119 infection. However, no significant differences were found between gender, HIV exposure
120 category and region of origin.

121 In the adjusted model, age at diagnosis is one of the factors associated with late presentation
122 (Table 2), patients with less than 30yo had lower probability of being LP than patients with
123 >56yo (aOR 0.34; 0.17-0.68; $p=0.002$). Patients from Sub-Saharan Africa had 2.24 more
124 probability of presenting late than those from Portugal (aOR 2.24; 1.44-3.50; $p<0.001$) and
125 patients presenting stage B or C had higher probability of being LP than those in stage A (aOR
126 2.95; 1.79-4.86 and aOR 10.16; 5.38-19.19); $p<0.001$ and $p<0.001$, respectively). The last
127 variable associated with late presentation was viral load at diagnosis, patients with a viral load
128 between 4.1-5.0 and >5.1 had higher probability than those with a viral load of <4.0 (aOR 3.40;
129 2.00-5.79 and aOR 7.01; 4.03-12.20; $p<0.001$ and $p<0.001$, respectively).

130 In the LPAD model (Table 2) the factors associated with late presentation with advanced
131 disease included stage of infection at diagnosis - patients presenting stage B or C had higher
132 probability than those in stage A (aOR 2.42; 1.35-4.35 and aOR 7.01; 3.79-12.98); $p=0.003$ and
133 $p<0.001$, respectively) and viral load at diagnosis - patients with a viral load between >5.1 had

134 higher probability of being LPAD than those with a viral load of <4.0 (aOR 3.10; 1.24-7.77;
135 $p=0.016$).

136 **Discussion**

137 This study had the goal of understanding the determinants of late presentation for HIV-1
138 infection.

139 In our population of patients, late presenters represented 50.6% of the patients. Of these,
140 61.9% were late presenters with advanced disease, which is consistent with the last national
141 report (2017) [2]. Our results are in accordance with overall European data (2017), in which
142 the late presenters account for 49% of the HIV cases, and 28% were late presenters with
143 advanced disease [12].

144 The proportion of late presenters were higher in male gender, patients with heterosexual
145 transmission, immigrants originated from Sub-Saharan Africa and patients aged between 31
146 and 55 years old. These results are consistent with other studies [8,11,13]. Patients originated
147 from Sub-Saharan Africa represent 23.9% of the study population, of those 28.8% were LP,
148 which is substantially lower when compared to a similar Belgian study, where the proportion
149 of patients from Sub-Saharan African represented 54.3% of the total. [14].

150 According to our results the stage A of infection had higher proportions for the LP population,
151 while in the LPAD population the higher proportion was for the stage C. This is expected and
152 can be considered as a partial validation for our assignment of LP and LPAD to patients groups
153 [15].

154 The results from previous studies showed statistically significant correlation between late
155 presentation and HIV exposure category [6,16,17]. While we did not find this significant
156 correlation in our logistic regression analysis, we did find it in the univariate analysis. However,

157 recent changes in the proportion of HIV exposure categories among new diagnoses could
158 confound such analysis [18,19].

159 The main goal of this study was to identify factors associated with late presentation and late
160 presentation with advanced disease. Those factors included age at diagnosis, region of origin,
161 stage of infection at diagnosis and \log_{10} of the viral load at diagnosis and were in concordance
162 with published studies [10,20] [11].

163 **Conclusion**

164 Even though Portugal has achieved the 90-90-90 objectives, the proportion of late presenters
165 is still very high, indicating that vulnerable populations are being left behind in screening
166 protocols. Late presentation is a high impact issue at individual, economic and social level. Our
167 study highlighted the main factors associated with that condition. Targeted prevention and
168 screening programs should be directed to these population.

169 **Funding:**

170 This study was financed by FCT through the following projects: MigrantsHIV PTDC/DTP-
171 EPI/7066/2014, BESTHOPE HIVERA: Harmonizing Integrating Vitalizing European Research on
172 HIV/Aids, grant 249697 and GHTM- UID/Multi/04413/2013 and Gilead Génese
173 HIVLatePresenters.

174 **References:**

- 175 [1] "HIV/AIDS." [Online]. Available: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/hiv-aids)
176 [sheets/detail/hiv-aids](https://www.who.int/news-room/fact-sheets/detail/hiv-aids). [Accessed: 18-Feb-2020].
- 177 [2] Portugal. Ministério da Saúde. Direção-Geral da Saúde/Instituto Nacional de Saúde
178 Doutor Ricardo Jorge. Infecção VIH e SIDA em Portugal - 2019. Lisboa: DGS/INSA; 2019

- 179 [3] "Understanding Fast-Track." [Online]. Available:
180 https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_Fast
181 [Track_en.pdf](https://www.unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_Fast_Track_en.pdf). [Accessed: 18-Feb-2020].
- 182 [4] UNAIDS, "Knowledge is power — Know your status, know your viral load." Available
183 from: [http://www.unaids.org/sites/default/files/media_asset/jc2940_knowledge-is-](http://www.unaids.org/sites/default/files/media_asset/jc2940_knowledge-is-power-report_en.pdf)
184 [power-report_en.pdf](http://www.unaids.org/sites/default/files/media_asset/jc2940_knowledge-is-power-report_en.pdf). [Accessed: 18-Feb-2020].
- 185 [5] S. Buetikofer, G. Wandeler, R. Kouyos, R. Weber, and B. Ledergerber, "Prevalence and
186 risk factors of late presentation for HIV diagnosis and care in a tertiary referral centre
187 in," no. April, pp. 1–8, 2014, doi: 10.4414/smw.2014.13961.
- 188 [6] A. Antinori *et al.*, "Late presentation of HIV infection: A consensus definition," *HIV*
189 *Med.*, vol. 12, no. 1, pp. 61–64, 2011, doi: 10.1111/j.1468-1293.2010.00857.x.
- 190 [7] H. N. Luma *et al.*, "Late presentation to HIV/AIDS care at the Douala general hospital,
191 Cameroon: Its associated factors, and consequences," *BMC Infect. Dis.*, vol. 18, no. 1,
192 pp. 1–9, 2018, doi: 10.1186/s12879-018-3204-8.
- 193 [8] C. C. Iwuji, D. Churchill, Y. Gilleece, H. A. Weiss, and M. Fisher, "Older HIV-infected
194 individuals present late and have a higher mortality: Brighton , UK cohort study," pp.
195 1–9, 2013.
- 196 [9] A. Guelar *et al.*, "Epidemiological characteristics and predictors of late presentation of
197 HIV infection in Barcelona (Spain) during the period 2001-2009," *AIDS Res. Ther.*, vol. 8,
198 no. 1, p. 22, 2011, doi: 10.1186/1742-6405-8-22.
- 199 [10] K. E. Darling, A. Hachfeld, M. Cavassini, O. Kirk, H. Furrer, and G. Wandeler, "Late
200 presentation to HIV care despite good access to health services: current
201 epidemiological trends and how to do better," *Swiss Med. Wkly.*, vol. 146, no. August,
202 p. w14348, 2016, doi: 10.4414/smw.2016.14348.

- 203 [11] E. L. M. Op De Coul *et al.*, “Factors associated with presenting late or with advanced HIV
204 disease in the Netherlands, 1996–2014: Results from a national observational cohort,”
205 *BMJ Open*, vol. 6, no. 1, pp. 1–10, 2016, doi: 10.1136/bmjopen-2015-009688.
- 206 [12] “HIV infection and AIDS Methods.” [Internet]. Available from:
207 [https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2017-hiv-infection-](https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2017-hiv-infection-aids_1.pdf)
208 [aids_1.pdf](https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2017-hiv-infection-aids_1.pdf). [Accessed: 18-Feb-2020].
- 209 [13] R. D. Smith, V. C. Delpech, A. E. Brown, and B. D. Rice, “HIV transmission and high rates
210 of late diagnoses among adults aged 50 years and over,” *Aids*, vol. 24, no. 13, pp. 2109–
211 2115, 2010, doi: 10.1097/QAD.0b013e32833c7b9c.
- 212 [14] G. Darcis *et al.*, “Factors associated with late presentation for HIV care in a single
213 Belgian reference center: 2006 – 2017,” no. May, pp. 1–6, 2018, doi: 10.1038/s41598-
214 018-26852-0.
- 215 [15] N. Dimitrova *et al.*, “Late disease stage at presentation to an HIV clinic in the era of free
216 antiretroviral therapy in sub-Saharan Africa,” *PLoS One*, vol. 32, no. 7, pp. 736–740,
217 2017, doi: 10.1371/journal.pone.0178059.
- 218 [16] M. K. Lazanas *et al.*, “Risk Factors and Outcomes for Late Presentation for HIV-Positive
219 Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological
220 Research Europe Study (COHERE),” *PLoS Med.*, vol. 10, no. 9, p. e1001510, 2013, doi:
221 10.1371/journal.pmed.1001510.
- 222 [17] K. Wójcik-cichy, O. Jabłonowska, and A. Piekarska, “The high incidence of late
223 presenters for HIV / AIDS infection in the Lodz province , Poland in the years 2009 –
224 2016: we are still far from the UNAIDS 90 % target,” *AIDS Care*, vol. 0, no. 0, pp. 1–4,
225 2018, doi: 10.1080/09540121.2018.1470306.
- 226 [18] S. M. Jenness, C. S. Murrill, K. L. Liu, T. Wendel, E. Begier, and H. Hagan, “Missed

227 opportunities for HIV testing among high-risk heterosexuals," *Sex. Transm. Dis.*, vol. 36,
228 no. 11, pp. 704–710, 2009, doi: 10.1097/OLQ.0b013e3181ab375d.

229 [19] S. E. Kellerman, A. Drake, A. Lansky, and R. M. Klevens, "Use of and Exposure to HIV
230 Prevention Programs and Services by Persons at High Risk for HIV," *AIDS Patient Care*
231 *STDS*, vol. 20, no. 6, pp. 391–398, 2006, doi: 10.1089/apc.2006.20.391.

232 [20] E. Raffetti *et al.*, "The risk of late or advanced presentation of HIV infected patients is
233 still high, associated factors evolve but impact on overall mortality is vanishing over
234 calendar years: Results from the Italian MASTER Cohort," *BMC Public Health*, vol. 16,
235 no. 1, 2016, doi: 10.1186/s12889-016-3477-z.

236

237

Table 1. Demographic and clinical patient characteristics

Patient Characteristics	Total	Late Presenters	Non-Late Presenters	p-value	Late Presenters with advanced disease	p-value
Gender, n (%)	907 (100%)	459 (50.6%)	448 (49.4%)	0.499	284 (61.9%)	0.403 ¹
Female	284 (31.3%)	139 (30.3%)	145 (32.4%)		82 (28.9%)	
Male	623 (68.7%)	320 (69.7%)	303 (67.6%)		202 (71.1%)	
Median age at diagnosis in years IQR, n (%)	806 (100%)	430 (53.3%)	376 (46.7%)	<0.001	264 (61.4%)	0.049 ²
	37.0 (30.0-47.0)	39.5 (32.0-50.0)	33.5 (28.0-43.0)		41.0 (32.25-51.0)	
<30	230 (28.5%)	89 (20.7%)	141 (37.5%)		46 (17.4%)	
31-55	488 (60.5%)	276 (64.2%)	212 (56.4%)		172 (65.2%)	
>56	88 (10.9%)	65 (15.1%)	23 (6.1%)	46 (17.4%)		
Type of transmission, n (%)	894 (100%)	453 (50.7%)	441 (49.3%)	0.001	278 (61.4%)	0.496 ¹
Heterosexual	468 (52.3%)	258 (57.0%)	210 (47.6%)		165 (59.4%)	
MSM	275 (30.8%)	113 (24.9%)	162 (36.7%)		66 (23.7%)	

IDU	141 (15.8%)	75 (16.6%)	66 (15.0%)		44 (15.8%)	
Other	10 (1.1%)	7 (1.5%)	3 (0.7%)		3 (1.1%)	
Region of origin, n (%)	899 (100%)	455 (50.6%)	444 (49.4%)	0.004	282 (62.0%)	0.893 ¹
Portugal	609 (67.7%)	293 (64.4%)	316 (71.2%)		181 (64.2%)	
Sub-Saharan Africa	215 (23.9%)	131 (28.8%)	84 (18.9%)		80 (28.4%)	
Brasil	54 (6.0%)	23 (5.1%)	31 (7.0%)		16 (5.7%)	
Other	21 (2.3%)	8 (1.8%)	13 (2.9%)		5 (1.8%)	
Stage of Infection at diagnosis, n (%)	895 (100%)	453 (50.6%)	442 (49.4%)	<0.001	276 (61.3%)	<0.001¹
A	598 (66.8%)	220 (48.6%)	378 (85.5%)		94 (34.1%)	
B	131 (14.6%)	84 (18.5%)	47 (10.6%)		54 (19.6%)	
C	166 (18.5%)	149 (32.9%)	17 (3.8%)		128 (46.4%)	
Median CD4 count at diagnosis (cells/mL) IQR, n (%)	907 (100%)	459 (50.6%)	448 (49.4%)		284 (61.9%)	
	342.0 (155.0-554.0)	158.0 (59.0-250.0)	555.5 (444.0-712.0)		83.5 (33.0-144.0)	

Viral Load at diagnosis (log₁₀ copies/mL) IQR, n (%)	785 (100%)	396 (50.4%)	389 (49.6%)	<0.001	241 (60.9%)	<0.001²
	4.8 (4.2-5.4)	5.1 (4.7-5.6)	4.4 (3.8-4.9)		5.3 (4.9-5.7)	
>4.0	146 (18.6%)	27 (6.8%)	119 (30.6%)	<0.001	11 (4.6%)	<0.001¹
4.1-5.0	322 (41.0%)	139 (35.1%)	183 (47.0%)		61 (25.3%)	
<5.1	317 (40.4%)	230 (58.1%)	87 (22.4%)		169 (70.1%)	

Other in mode of transmission include transfusions; Other in region of origin include European, Latin and North American Countries; p-values retrieved with t-test and chi-square test; MSM- Men have sex with men; IDU- Injection drug users

Table 2. Univariate and multivariate logistic regression analysis of factors associated with late presentation and late presentation with advanced disease

		LP vs NLP				LP vs LPAD			
		Unadjusted		Final Model		Unadjusted		Final Model	
		OR (95%CI)	p-value	aOR (95%CI)	p-value	OR (95%CI)	p-value	aOR (95%CI)	p-value
Sex	Female	Ref		Ref		Ref		Ref	
	Male	1.10 (0.83-1.46)	0.499	1.07 (0.73-1.58)	0.732	1.19 (0.79-1.79)	0.403	0.91 (0.54-1.51)	0.706
Age at diagnosis		1.04 (1.03-1.05)	<0.001			1.02 (1.00-1.03)	0.048		
Age groups	<30	0.22 (0.13-0.39)	<0.001	0.34 (0.17-0.68)	0.002	0.44 (0.22-0.87)	0.018	0.60 (0.27-1.35)	0.216
	31-55	0.46 (0.28-0.77)	0.003	0.54 (0.19-1.03)	0.060	0.68 (0.38-1.23)	0.203	0.72 (0.36-1.43)	0.347
	>56	Ref		Ref		Ref		Ref	
Type of transmission	Heterosexual	Ref		Ref		Ref		Ref	
	MSM	0.57 (0.42-0.77)	<0.001			0.79 (0.50-1.24)	0.311		

	IDU	0.93 (0.63-1.35)	0.686			0.80 (0.47-1.35)	0.405		
	Other	1.90 (0.49-7.44)	0.357			0.42 (0.09-1.93)	0.266		
Region of origin	Portugal	Ref		Ref		Ref			
	Sub-Saharan Africa	1.68 (1.23-2.31)	0.001	2.24 (1.44-3.50)	<0.001	0.97 (0.64-1.48)	0.890		
	Brasil	0.80 (0.46-1.40)	0.437	0.68 (0.31-1.51)	0.349	1.41 (0.56-3.55)	0.460		
	Other	0.66 (0.27-1.62)	0.369	0.47 (0.15-1.43)	0.181	1.03 (0.24-4.40)	0.967		
Stage of infection at diagnosis	A	Ref		Ref		Ref		Ref	
	B	3.07 (2.07-4.55)	<0.001	2.95 (1.79-4.86)	<0.001	2.41 (1.43-4.06)	0.001	2.42 (1.35-4.35)	0.003
	C	15.06 (8.88-25.55)	<0.001	10.16 (5.38-19.19)	<0.001	9.53 (5.44-16.71)	<0.001	7.01 (3.79-12.98)	<0.001
Viral load at diagnosis		2.71 (2.23-3.30)	<0.001			2.08 (1.57-2.75)	<0.001		

Viral load groups	<4.0	Ref		Ref		Ref		Ref	
	4.1-5.0	3.35 (2.09-5.37)	<0.001	3.40 (2.00-5.79)	<0.001	1.14 (0.49-2.63)	0.763	1.14 (0.45-2.90)	0.788
	>5.1	11.65 (7.17-18.93)	<0.001	7.01 (4.03-12.20)	<0.001	4.03 (1.77-9.16)	0.001	3.10 (1.24-7.77)	0.016

Other in mode of transmission include transfusions; Other in region of origin include European, Latin and North American Countries; p-values retrieved with t-test and chi-square test; MSM- Men have sex with men; IDU- Injection drug users; Ref- Reference Category